Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

274
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
274
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

612
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
612
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

431
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
431

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimated Glomerular Filtration Rate Reporting From Whole Blood Creatinine: A Proficiency Testing Survey.

Archives of pathology & laboratory medicine·2025
Same author

Large Language Models Lack Sufficient Performance to Provide Definitive Regulatory Guidance.

The journal of applied laboratory medicine·2025
Same author

Laboratory-developed tests and in vitro diagnostics: A regulatory overview for anatomic pathology.

American journal of clinical pathology·2025
Same author

FDA's Final Rule on Laboratory Developed Tests.

Clinical chemistry·2024
Same author

Reported Awareness and Use of Pyridoxal-5'-Phosphate Supplementation in Alanine Aminotransferase and Aspartate Aminotransferase Assay Reagents: A Survey by the College of American Pathologists Clinical Chemistry Committee.

Archives of pathology & laboratory medicine·2024
Same author

The US FDA's proposed rule on laboratory-developed tests: Impacts on clinical laboratory testing.

Practical laboratory medicine·2024
Same journal

Comparison of Information-Dependent Acquisition and Sequential Window Acquisition of All Theoretical Mass Spectra for Untargeted Drug Testing on a Linear Ion Trap-Pulsing Quadrupole-Time of Flight Mass Spectrometer.

Clinical chemistry·2026
Same journal

Patterns of One-Year Change in HbA1c and Continuous Glucose Monitoring (CGM) Metrics in Older Adults with Type 2 Diabetes.

Clinical chemistry·2026
Same journal

TSH Pediatric Reference Intervals: Lack of CALIPER Applicability to US-Based Populations.

Clinical chemistry·2026
Same journal

Rapid Detection of Hemoglobinopathy Variants Using One-Step Library Preparation and Nanopore Sequencing.

Clinical chemistry·2026
Same journal

Editor's Note: Circulating Proteolytic Products of Carboxypeptidase N for Early Detection of Breast Cancer.

Clinical chemistry·2026
Same journal

In Reply to Reflexing NT-proBNP for sFlt-1/PlGF Ratios That Fall into the Measurement Uncertainty for Preeclampsia Risk Classification.

Clinical chemistry·2026
See all related articles

Related Experiment Video

Updated: Feb 27, 2026

Detection of Endotoxin in Nano-formulations Using Limulus Amoebocyte Lysate LAL Assays
06:15

Detection of Endotoxin in Nano-formulations Using Limulus Amoebocyte Lysate LAL Assays

Published on: January 30, 2019

15.5K

Laboratory-Developed Tests: A Legislative and Regulatory Review.

Jonathan R Genzen1,2, Jeffrey S Mohlman3,2, Jerry L Lynch4

  • 1Department of Pathology, University of Utah, Salt Lake City, UT; jonathan.genzen@path.utah.edu.

Clinical Chemistry
|July 9, 2017
PubMed
Summary
This summary is machine-generated.

Regulatory oversight for laboratory-developed tests (LDTs) remains uncertain despite FDA

More Related Videos

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
07:43

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices

Published on: July 14, 2023

2.9K
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.5K

Related Experiment Videos

Last Updated: Feb 27, 2026

Detection of Endotoxin in Nano-formulations Using Limulus Amoebocyte Lysate LAL Assays
06:15

Detection of Endotoxin in Nano-formulations Using Limulus Amoebocyte Lysate LAL Assays

Published on: January 30, 2019

15.5K
Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
07:43

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices

Published on: July 14, 2023

2.9K
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.5K

Area of Science:

  • Regulatory science
  • In vitro diagnostics
  • Clinical laboratory operations

Background:

  • The Food and Drug Administration (FDA) has long considered laboratory-developed tests (LDTs) subject to regulatory oversight.
  • A 2014 draft guidance on LDT oversight sparked debate, but remains unimplemented, leaving regulatory questions unresolved.

Purpose of the Study:

  • To review federal statutes and regulations pertinent to in vitro diagnostics (IVDs) and clinical laboratory operations.
  • To analyze regulatory efforts potentially applicable to LDTs and identify sources of community uncertainty.

Main Methods:

  • Review of federal statutes and regulations (Code of Federal Regulations, Federal Register).
  • Analysis of congressional hearings, FDA guidance and policy documents, and published literature.

Main Results:

  • Federal IVD statutes predate explicit consideration of LDTs.
  • The FDA possesses clear oversight authority over IVD reagents in commerce.
  • A 16-year delay in asserting authority, draft guidance, and CLIA'88 regulations created uncertainty regarding LDT oversight.

Conclusions:

  • Existing federal statutes were enacted without specific consideration for LDTs.
  • FDA's historical approach and existing regulations have contributed to ambiguity in LDT oversight.
  • Future regulatory or legislative action may be necessary to clarify LDT oversight.